TY - JOUR
T1 - Serum free fatty acid biomarkers of lung cancer
AU - Liu, Jinbo
AU - Mazzone, Peter J.
AU - Cata, Juan P.
AU - Kurz, Andrea
AU - Bauer, Maria
AU - Mascha, Edward J.
AU - Sessler, Daniel I.
N1 - Funding Information:
FUNDING/SUPPORT: This study was funded in part by the Joseph Drown Foundation (Los Angeles, CA).
PY - 2014/9/1
Y1 - 2014/9/1
N2 - BACKGROUND: Lung cancer is the leading cause of cancer-related mortality. Surgical removal of the tumor at an early stage can be curative. However, lung cancer diagnosis at an early stage remains challenging. There is evidence that free fatty acids play a role in cancer development.METHODS: Serum samples from 55 patients with lung cancer were propensity matched with samples from 165 similar pulmonary patients without known cancer. Patients were propensity matched on age, sex, smoking history, family history of lung cancer, and chronic diseases that might affect free fatty acid levels.RESULTS: Free fatty acids arachidonic acid (AA) and linoleic acid (LA) and their metabolites hydroxyeicosatetraenoic acids (HETEs)(5-HETE, 11-HETE, 12-HETE, and 15-HETE) were an estimated 1.8-to 3.3-fold greater in 37 patients with adenocarcinoma vs 111 patients without cancer (all P < .001). Areas under the receiver operating characteristic curve were significantly > 0.50, discriminating patients with lung cancer and control subjects for six of eight biomarkers and two of seven phospholipids tested, and ranged between 0.69 and 0.82 (all P < .001) for patients with lung cancer vs control subjects. AA, LA, and 15-HETE had observed sensitivity and specificity > 0.70 at the best cutpoint. Concentrations of free fatty acids and their metabolites were similar in 18 patients with squamous cell carcinoma and 54 control subjects without cancer.CONCLUSIONS: Serum fatty acids and their metabolites demonstrate good sensitivity and specificity for the identification of adenocarcinoma of the lung.
AB - BACKGROUND: Lung cancer is the leading cause of cancer-related mortality. Surgical removal of the tumor at an early stage can be curative. However, lung cancer diagnosis at an early stage remains challenging. There is evidence that free fatty acids play a role in cancer development.METHODS: Serum samples from 55 patients with lung cancer were propensity matched with samples from 165 similar pulmonary patients without known cancer. Patients were propensity matched on age, sex, smoking history, family history of lung cancer, and chronic diseases that might affect free fatty acid levels.RESULTS: Free fatty acids arachidonic acid (AA) and linoleic acid (LA) and their metabolites hydroxyeicosatetraenoic acids (HETEs)(5-HETE, 11-HETE, 12-HETE, and 15-HETE) were an estimated 1.8-to 3.3-fold greater in 37 patients with adenocarcinoma vs 111 patients without cancer (all P < .001). Areas under the receiver operating characteristic curve were significantly > 0.50, discriminating patients with lung cancer and control subjects for six of eight biomarkers and two of seven phospholipids tested, and ranged between 0.69 and 0.82 (all P < .001) for patients with lung cancer vs control subjects. AA, LA, and 15-HETE had observed sensitivity and specificity > 0.70 at the best cutpoint. Concentrations of free fatty acids and their metabolites were similar in 18 patients with squamous cell carcinoma and 54 control subjects without cancer.CONCLUSIONS: Serum fatty acids and their metabolites demonstrate good sensitivity and specificity for the identification of adenocarcinoma of the lung.
UR - http://www.scopus.com/inward/record.url?scp=84907189040&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907189040&partnerID=8YFLogxK
U2 - 10.1378/chest.13-2568
DO - 10.1378/chest.13-2568
M3 - Article
C2 - 24743744
AN - SCOPUS:84907189040
SN - 0012-3692
VL - 146
SP - 670
EP - 679
JO - Diseases of the chest
JF - Diseases of the chest
IS - 3
ER -